Template:HIV post-exposure prophylaxis regimens: Difference between revisions
No edit summary
Line 2: Line 2:
*[[Raltegravir]] (Isentress; RAL) 400 mg PO twice daily, '''plus'''
*[[Raltegravir]] (Isentress; RAL) 400 mg PO twice daily, '''plus'''
*[[Truvada]], 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg)
*[[Truvada]], 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg)
===3 drug Expanded<ref name="NEJM"></ref>===
*Ritonavir–lopinavir (Kaletra) PLUS either tenofovir–emtricitabine or zidovudine–lamivudine)
**Two tablets (50 mg of ritonavir with 200 mg of lopinavir per tablet) twice daily, or four tablets once daily
*Ritonavir plus atazanavir (plus either tenofovir–emtricitabine or zidovudine–lamivudine
**100 mg of ritonavir plus 300 mg of atazanavir once daily
*Ritonavir plus darunavir (plus either tenofovir–emtricitabine or zidovudine–lamivudine)
**100 mg of ritonavir plus two tablets, each containing 400 mg of darunavir, once daily

Revision as of 18:40, 19 November 2017

Preferred HIV PEP Regimen[1][2]

  • Raltegravir (Isentress; RAL) 400 mg PO twice daily, plus
  • Truvada, 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg)
  1. ↑ Kuhar D, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. September 2013. 34(9):875-892. DOI: 10.1086/672271. http://www.jstor.org/stable/10.1086/672271
  2. ↑ Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services
Retrieved from "https://www.wikem.org/w/index.php?title=Template:HIV_post-exposure_prophylaxis_regimens&oldid=164649"